ERLOCIP 100 MG Erlotinib №30

ERLOCIP 100 MG instructions for use

The drug ERLOCIP 100-30 TAB CIPLA is capable of affecting tumor cells. This is a modern medicine with proven effectiveness.

Release form: tablets.

One package contains 30 tablets.

Indications for use

The drug is prescribed for non-small cell lung cancer with metastases and pancreatic cancer.

Advantages of the drug

Compared to analogues, the drug is characterized by:

1. a small percentage of the free fraction;
2. most of the components of the drug are absorbed by isoenzymes;
3. minimum contraindications;
4. fast absorption;
5. high bioavailability.

A separate advantage is the large percentage of the active substance — erlotinib. Each tablet contains 100 mg. of this substance.

Pharmacology

The main active substance erlotinib is an antitumor component. It activates the processes of destruction of cancer cells, prevents their growth and spread throughout the body by slowing down the intracellular phosphorylation of special receptors.

Dosages and regimens

The single dosage and dosage regimen are determined by the attending physician, taking into account the individual characteristics of the patient’s body and the course of the disease. The daily dosage of ERLOCIP 100-30 TAB CIPLA is 1 tablet. It should be taken orally over 60 minutes. before meals or after 120 minutes. after meal. The course may be adjusted. If the disease continues to progress, the drug should be discontinued.

The drug can be used only as prescribed by a doctor. It is sold exclusively by prescription.

Contraindications

The main contraindications to taking ERLOCIP 100 CIPLA are severe liver or kidney failure. The drug is not prescribed to children under 18 years of age. Its use is contraindicated during pregnancy, individual intolerance to the main components. The medicine is also contraindicated for women who are breastfeeding.

Relative contraindications to taking the drug are smoking and moderate liver failure. In these cases, the drug should be taken under strict medical supervision.

Possible adverse reactions

The following side effects often occur when taking ERLOCIP 100:

• disorders of the gastrointestinal tract;
• inflammation of the conjunctiva;
• nosebleeds;
• fast fatiguability;
• shortness of breath with minor physical exertion;
• headache;
• skin rashes on the body of erythematous or papulopustular types.

If any adverse reactions occur, you should inform your doctor.

Features of the drug use

ERLOCIP 100 may affect driving and operating various mechanisms. The drug should be taken before the expiration date indicated on the package.

Storage recommendations

ERLOCIP 100 CIPLA should be stored in a dark place at a temperature not exceeding 25°C. It is important that the place where the medicine is stored is inaccessible to children.